Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO)

July 11, 2023 updated by: Carien Creutzberg, Leiden University Medical Center

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features: the p53abn-RED Trial, the MMRd-GREEN Trial, the NSMP-ORANGE Trial and the POLEmut-BLUE Trial

The RAINBO umbrella program consists of four clinical trials investigating new adjuvant therapies in endometrial cancer patients. Eligible patients will be assigned to one of the four RAINBO trials based on the molecular profile of their cancer:

  • p53 abnormal endometrial cancer patients to the p53abn-RED trial
  • mismatch repair deficient endometrial cancer patients to the MMRd-GREEN trial
  • no specific molecular profile endometrial cancer patients to NSMP-ORANGE trial
  • POLE mutant endometrial cancer patients to the POLEmut-BLUE trial

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The p53abn-RED trial (NCT05255653-1) is an international, multicenter, phase III randomised trial wherein adjuvant chemoradiation followed by olaparib for two years is compared to adjuvant chemoradiation.

The MMRd-GREEN trial (NCT05255653-2) is an international, multicenter, phase III randomised trial wherein adjuvant pelvic external beam radiotherapy combined with and followed by durvalumab for one year is compared to adjuvant pelvic external beam radiotherapy.

The NSMP-ORANGE trial (NCT05255653-3) is an international, multicenter, phase III randomised trial wherein adjuvant pelvic external beam radiotherapy followed by progestogens for two years is compared to adjuvant chemoradiation.

The POLEmut-BLUE trial (NCT05255653-4) is an international, multicenter, single arm, phase II trial wherein safety of de-escalation of adjuvant therapy is investigated: no adjuvant therapy for stage I-II disease and no adjuvant therapy or pelvic external beam radiotherapy only for stage III disease.

The overarching RAINBO research project will combine the data and tumor material of the four RAINBO clinical trials to perform translational research and compare molecular profile-based adjuvant therapy to standard adjuvant therapy in terms of effectiveness, toxicity, quality of life and cost utility.

Study Type

Interventional

Enrollment (Estimated)

1615

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Canada
      • Toronto, Canada
        • Recruiting
        • The POLEmut-BLUE trial: Princess Margaret Cancer Centre, University of Toronto
        • Contact:
      • Vancouver, Canada
        • Recruiting
        • The POLEmut-BLUE trial: University of British Columbia
        • Contact:
  • France
  • Netherlands
      • Amsterdam, Netherlands
      • Breda, Netherlands
      • Breda, Netherlands
        • Recruiting
        • Instituut Verbeeten
        • Contact:
      • Den Haag, Netherlands
      • Eindhoven, Netherlands
      • Enschede, Netherlands
        • Recruiting
        • Medisch Spectrum Twente
        • Contact:
      • Groningen, Netherlands
        • Recruiting
        • Universitair Medisch Centrum Groningen
        • Contact:
      • Leiden, Netherlands, 2333ZA
        • Recruiting
        • The MMRd-GREEN trial: Leiden University Medical Center
        • Contact:
        • Contact:
      • Rotterdam, Netherlands
  • United Kingdom
      • London, United Kingdom
        • Not yet recruiting
        • The NSMP-ORANGE trial: Barts Health NHS Trust
        • Contact:
      • Manchester, United Kingdom
        • Not yet recruiting
        • The NSMP-ORANGE trial: Manchester Academic Health Science Centre, St Mary's Hospita
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Participants of the four RAINBO trials should be eligible according to the inclusion and exclusion criteria of both the overarching RAINBO trials program and the clinical trial that they are assigned to based on the molecular profile.

Inclusion Criteria of the overarching RAINBO program:

  • Histologically confirmed diagnosis of endometrial cancer (EC) of the following histotypes: endometrioid endometrial carcinoma, serous endometrial carcinoma, uterine clear cell carcinoma, dedifferentiated and undifferentiated endometrial carcinoma, uterine carcinosarcoma and mixed endometrial carcinomas of the aforementioned histotypes.
  • Full molecular classification performed following the diagnostic algorithm described in WHO 2020 (5th Edition, IARC, Lyon, 2020)
  • Hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy or sentinel node biopsy, without macroscopic residual disease after surgery
  • No distant metastases as determined by pre-surgical or post-surgical imaging (CT scan of chest, abdomen and pelvis or whole-body PET-CT scan)
  • WHO performance status 0, 1 or 2
  • Expected start of adjuvant treatment (if applicable) within 10 weeks after surgery
  • Patients must be accessible for treatment and follow-up
  • Written informed consent for participation in one of the RAINBO trials, permission for the contribution of a tissue block for translation research and permission for the use and sharing of data for the overarching research project according to the local Ethics Committee requirements.

Exclusion Criteria overarching RAINBO program:

  • History of another primary malignancy, except for non-melanoma skin cancer, in the past 5 years
  • Prior pelvic radiation

The p53abn-RED trial

Inclusion criteria:

  • p53 abnormal EC
  • Histologically confirmed stage I (with invasion) II or III EC
  • WHO Performance score 0-1
  • Body weight > 30 kg

  • Adequate systemic organ function:

    • Creatinine clearance (> 40 cc/min): Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
    • Adequate bone marrow function : hemoglobin >9.0 g/dl, Absolute neutrophil count (ANC) ≥1.0 x 109/l, platelet count ≥75 x 109/l.
    • Adequate liver function: bilirubin ≤1.5 x institutional upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician, AND ALT (SGPT) and/or AST (SGOT) ≤2.5 x ULN

Exclusion criteria:

  • Pathogenic POLE mutation(s)
  • Mismatch repair deficiency
  • Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of the IP
  • History of allogenic organ transplantation
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
  • Any previous treatment with a PARP inhibitor, including olaparib
  • History of active primary immunodeficiency
  • History or evidence of hemorrhagic disorders within 6 months prior to randomization
  • Patients with myelodysplastic syndrome/acute myeloid leukemia history or with features suggestive of MDS/AML
  • Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
  • Active infection, including: tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immuno-deficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
  • Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  • Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  • Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.

The MMRd-GREEN trial

Inclusion criteria:

  • Mismatch repair deficient EC
  • Histologically confirmed Stage III EC or stage IB/II EC with substantial lympovascular space invasion (LVSI)
  • WHO Performance score 0-1
  • Body weight > 30 kg

  • Adequate systemic organ function:

    • Creatinine clearance (> 40 cc/min): Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
    • Adequate bone marrow function : hemoglobin >9.0 g/dl, Absolute neutrophil count (ANC) ≥1.0 x 109/l, platelet count ≥75 x 109/l.
    • Adequate liver function: bilirubin ≤1.5 x institutional upper limit of normal (ULN). <<This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.>> AND ALT (SGPT) and/or AST (SGOT) ≤2.5 x ULN

Exclusion criteria:

  • Pathogenic POLE mutation(s)
  • Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of investigational medicinal product (IMP)
  • History of allogenic organ transplantation
  • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
  • Any previous treatment with a PD(L)1 inhibitor, including durvalumab.
  • Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IMP.

  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab with the exceptions of:

    • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection).
    • Systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent.
    • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
  • History of active primary immunodeficiency

  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome. The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome)stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician.
  • Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immuno-deficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.

The NSMP-ORANGE trial

Inclusion criteria:

  • NSMP EC
  • Histologically confirmed stage II EC with substantial LVSI or stage III EC
  • ER positive EC
  • WHO performance status 0-1

Exclusion criteria:

  • Pathogenic POLE mutation(s)
  • Mismatch repair deficiency
  • p53 abnormality

The POLEmut-BLUE trial

Inclusion criteria:

  • Pathogenic POLE mutation(s)

  • For the main cohort, patients must have one of the following combinations of FIGO stage, grade, and LVSI:

    • stage IA (not confined to polyp), grade 3, pN0, with or without LVSI
    • stage IB, grade 1 or 2, pNx/N0, with or without LVSI
    • stage IB, grade 3, pN0, without substantial LVSI
    • stage II (microscopic), grade 1 or 2, pN0, without substantial LVSI

  • For the exploratory cohort, patients must have one of the following combinations of FIGO stage, grade, and LVSI:

    • stage IA (not confined to polyp), grade 3, pNx, with or without LVSI
    • stage IB, grade 3, pNx, with or with LVSI.
    • stage IB, grade 3, pN0, with substantial LVSI.
    • stage II (microscopic), grade 1 or 2, pNx, with or without LVSI.
    • stage II (microscopic), grade 1 or 2, pN0, with substantial LVSI.
    • stage II (microscopic), grade 3, pNx/N0, with or without LVSI.
    • stage II non-microscopic, any grade, pNx/N0, with or without LVSI.
    • stage III, any grade, pNx/N0-2, with or without LVSI.
  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrolment in the trial to document their willingness to participate. A similar process must be followed for sites outside of Canada as per their respective cooperative group's procedures.
  • Patient is able (i.e., sufficiently fluent) and willing to complete the QOL and/or health utility questionnaires in either English, French or a validated language. The baseline assessment must be completed within the required timelines, prior to enrolment. Inability (lack of comprehension in English or French, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible.
  • Patients must be accessible for treatment and follow up. Patients enrolled on this trial must be treated and followed at the participating center. Investigators must assure themselves the patients enrolled on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
  • Patients must agree to return to their primary care facility for any adverse events which may occur through the course of the trial.
  • In accordance with CCTG policy, protocol treatment is to begin within 10 weeks of hysterectomy/bilateral salpingo-oophorectomy.

Exclusion criteria:

  • Prior chemotherapy for EC
  • Isolated tumor cells identified in lymph node(s) for main study cohort (patient can be included in exploratory cohort)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: MMRd-GREEN trial: control
Adjuvant pelvic external beam radiotherapy
Radiation: Pelvic external beam radiotherapy
45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
Other Names:
  • EBRT
Radiation: Vaginal brachytherapy
Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Experimental: p53abn-RED trial: experimental
Adjuvant radiotherapy and chemotherapy followed by olaparib (lynparza), 300 mg twice daily, for two years
Drug: Olaparib
300 mg twice daily for two years
Other Names:
  • Lynparza
Radiation: Pelvic external beam radiotherapy
45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
Other Names:
  • EBRT
Drug: Chemotherapy
Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
Other Names:
  • Cisplatin
  • Carboplatin
  • Paclitaxel
Radiation: Vaginal brachytherapy
Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Active Comparator: p53abn-RED trial: control
Adjuvant radiotherapy and chemotherapy
Radiation: Pelvic external beam radiotherapy
45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
Other Names:
  • EBRT
Drug: Chemotherapy
Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
Other Names:
  • Cisplatin
  • Carboplatin
  • Paclitaxel
Radiation: Vaginal brachytherapy
Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Experimental: MMRd-GREEN trial: experimental
Adjuvant radiotherapy combined with and followed by durvalumab, 1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles)
Radiation: Pelvic external beam radiotherapy
45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
Other Names:
  • EBRT
Drug: Durvalumab
1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles) starting within the first week of radiotherapy,
Other Names:
  • Imfinzi
Radiation: Vaginal brachytherapy
Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Experimental: NSMP-ORANGE trial: experimental
Adjuvant radiotherapy followed by oral progestagens (medroxyprogesterone acetate or megestrol acetate) for two years
Radiation: Pelvic external beam radiotherapy
45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
Other Names:
  • EBRT
Drug: Medroxyprogesterone Acetate
Oral medroxyprogesterone acetate for two years
Other Names:
  • Progestogen
Drug: Megestrol Acetate
Oral medroxyprogesterone acetate for two years
Other Names:
  • Progestogen
Radiation: Vaginal brachytherapy
Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Active Comparator: NSMP-ORANGE trial: control
Adjuvant radiotherapy and chemotherapy
Radiation: Pelvic external beam radiotherapy
45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
Other Names:
  • EBRT
Drug: Chemotherapy
Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam radiotherapy followed by four cycles of intravenous carboplatin AUC 5 and paclitaxel 175 mg/m² at 21-day intervals.
Other Names:
  • Cisplatin
  • Carboplatin
  • Paclitaxel
Radiation: Vaginal brachytherapy
Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Other: POLEmut-BLUE trial: main cohort

No adjuvant therapy in women with:

  • stage IA (not confined to polyp), grade 3, pN0, with or without LVSI
  • stage IB, grade 1 or 2, pNx/N0, with or without LVSI
  • stage IB, grade 3, pN0, without substantial LVSI
  • stage II (microscopic), grade 1 or 2, pN0, without substantial LVSI
Other: Observation
No adjuvant therapy
Other: POLEmut-BLUE trial: exploratory cohort

No adjuvant therapy or vaginal brachytherapy or pelvic external beam radiotherapy in women with:

  • stage IA (not confined to polyp), grade 3, pNx, with or without LVSI
  • stage IB, grade 3, pNx, with or with LVSI.
  • stage IB, grade 3, pN0, with substantial LVSI.
  • stage II (microscopic), grade 1 or 2, pNx, with or without LVSI.
  • stage II (microscopic), grade 1 or 2, pN0, with substantial LVSI.
  • stage II (microscopic), grade 3, pNx/N0, with or without LVSI.
  • stage II non-microscopic, any grade, pNx/N0, with or without LVSI.
  • stage III, any grade, pNx/N0-2, with or without LVSI.
Radiation: Pelvic external beam radiotherapy
45.0-48.6 Gy; 1.8-2.0 Gy per fraction, 5 fractions a week
Other Names:
  • EBRT
Radiation: Vaginal brachytherapy
Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Other: Observation
No adjuvant therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
p53abn-RED trial
Time Frame: 3 years
Recurrence-free survival
3 years
MMRd-GREEN trial
Time Frame: 3 years
Recurrence-free survival
3 years
NSMP-ORANGE trial
Time Frame: 3 years
Recurrence-free survival
3 years
POLEmut-BLUE trial
Time Frame: 3 years
Pelvic recurrence-free survival
3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recurrence-free survival
Time Frame: 5 years
All RAINBO trials
5 years
Pelvic recurrence-free survival
Time Frame: 5 years
All RAINBO trials
5 years
Vaginal recurrence-free survival
Time Frame: 3 years, 5 years
All RAINBO trials
3 years, 5 years
Endometrial cancer-specific survival
Time Frame: 3 years, 5 years
All RAINBO trials
3 years, 5 years
Overall survival
Time Frame: 3 years, 5 years
All RAINBO trials
3 years, 5 years
Treatment-related toxicity - according to CTCAE v5.0
Time Frame: 3 years, 5 years
All RAINBO trials
3 years, 5 years
Health-related quality of life - Assessed using the EORTC QLQ-C30 questionnaire
Time Frame: 3 years, 5 years
All RAINBO trials
3 years, 5 years
Health-related quality of life - Assessed using the EORTC QLQ-EN24 questionnaire
Time Frame: 3 years, 5 years
All RAINBO trials
3 years, 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Leiden University Medical Center

Collaborators

Canadian Institutes of Health Research (CIHR)
AstraZeneca
National Cancer Institute, France
Comprehensive Cancer Centre The Netherlands
Dutch Cancer Society
Cancer Research UK & UCL Cancer Trials Centre
Institute Gustave Roussy (sponsor p53abn-RED trial)
Leiden University Medical center (sponsor MMRd-GREEN trial)
University College London (sponsor NSMP-ORANGE trial)
Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial)
Dutch Gynaecological Oncology Group

Investigators

  • Principal Investigator: Alexandra Leary, Md PhD, Institute Gustave Roussy, Villejuif, France (p53abn-RED trial)
  • Principal Investigator: Judith R Kroep, MD PhD, Leiden University Medical Center, Leiden, The Netherlands (MMRd-GREEN trial)
  • Principal Investigator: Melanie E Powell, Md PhD, Barts Health NHS Trust, London, United Kingdom (NSMP-ORANGE trial)
  • Principal Investigator: Emma J Crosbie, Md PhD, St Mary's Hospital, Manchester, United Kingdom (NSMP-ORANGE trial)
  • Principal Investigator: Kathy Han, Md PhD, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada (POLEmut-BLUE trial)
  • Principal Investigator: Jessica N McAlpine, Md PhD, University of British Columbia,Vancouver, Canada (POLEmut-BLUE trial)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 11, 2021

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2031

Study Registration Dates

First Submitted

February 1, 2022

First Submitted That Met QC Criteria

February 15, 2022

First Posted (Actual)

February 24, 2022

Study Record Updates

Last Update Posted (Actual)

July 13, 2023

Last Update Submitted That Met QC Criteria

July 11, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RAINBO
  • ENGOT-en14-1,2,3,4 (Other Identifier: ENGOT)
  • CCTG EN.10 TAPER arm A POLE (Other Identifier: CCTG (only for the POLEmut-BLUE trial))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Following the planned translational work in the RAINBO programme and publications, the translational research (TR) committee will open up the sample collection to external researchers. Access will be granted following completion of a research proposal form and approval by the TR committee chaired by Dr. Tjalling Bosse. All external researchers will be expected to demonstrate funding for their project and ethics approval. Data will be made available as required through data sharing agreements. The following will be reviewed when considering applications for data sharing and sample access: data and sample use is in-keeping with patient consent, the proposed project has scientific value, with defined objectives and study plan, trial data are appropriate for the intended purpose, acknowledgement of the RAINBO Programme in all publications that arise from the data sharing, compliance with legal and regulatory requirements as applicable and patient confidentiality maintained at all times.

IPD Sharing Time Frame

The study protocols of the four trials will be made made available on the trial's websites by the time the trials open

IPD Sharing Access Criteria

Public

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endometrial Cancer

Clinical Trials on Olaparib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe